Literature DB >> 19402791

Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmocheck study.

Concetta Prontera1, Martina Zaninotto, Stefania Giovannini, Gian Carlo Zucchelli, Alessandro Pilo, Laura Sciacovelli, Mario Plebani, Aldo Clerico.   

Abstract

BACKGROUND: We organized and conducted a proficiency testing study (CardioOrmocheck) to evaluate the differences in analytical performance of brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) immunoassays.
METHODS: Approximately 90 Italian laboratories were involved in the 2005-2007 proficiency testing cycles, while 112 laboratories took part in the 2008 cycle (from January to May 2008). A total of 28 study samples were measured by participating laboratories for a total of 2354 determinations.
RESULTS: The mean total variability for BNP (50.6 %CV) was significantly higher than that for NT-proBNP (8.4 %CV). In addition, the mean variability due to differences between-methods (46.4 %CV) comprised the majority of the total variability for BNP. Between-method variability for BNP comprised, on average, 84% of total variability, while the within-method variability comprised an average of 20.2 %CV. On the contrary, for NT-proBNP the within-method variability (7.3 %CV) represented the majority of total variability (average 75%), while between-method variability was smaller (4.1 %CV). Imprecision around the cut-off value showed marked differences among methods, especially for BNP immunoassay methods. In addition, BNP methods were affected by large systematic differences, for example an average 2.7-fold difference between Access and ADVIA Centaur methods, while agreement between NT-proBNP methods was better (an average 1.2-fold difference between Dimension and ECLIA on the Elecsys methods).
CONCLUSIONS: This multicenter collaborative study demonstrates that there are significant differences in analytical characteristics and measured values among the most popular commercial methods for BNP and NT-proBNP. Clinicians should be very careful when comparing results obtained by laboratories that use different methods.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19402791     DOI: 10.1515/CCLM.2009.153

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  8 in total

Review 1.  The paradox of low BNP levels in obesity.

Authors:  Aldo Clerico; Alberto Giannoni; Simona Vittorini; Michele Emdin
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

2.  Status of internal quality control for thyroid hormones immunoassays from 2011 to 2016 in China.

Authors:  Shishi Zhang; Wei Wang; Haijian Zhao; Falin He; Kun Zhong; Shuai Yuan; Zhiguo Wang
Journal:  J Clin Lab Anal       Date:  2017-02-15       Impact factor: 2.352

Review 3.  Interpretation and use of natriuretic peptides in non-congestive heart failure settings.

Authors:  Shih-Hung Tsai; Yen-Yue Lin; Shi-Jye Chu; Ching-Wang Hsu; Shu-Meng Cheng
Journal:  Yonsei Med J       Date:  2010-02-12       Impact factor: 2.759

Review 4.  The potential and limitations of plasma BNP measurement in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an update.

Authors:  Massimiliano Cantinotti; Yuk Law; Simona Vittorini; Maura Crocetti; Marotta Marco; Bruno Murzi; Aldo Clerico
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

Review 5.  Brain natriuretic peptide for prediction of mortality in patients with sepsis: a systematic review and meta-analysis.

Authors:  Fei Wang; Youping Wu; Lu Tang; Weimin Zhu; Feng Chen; Tao Xu; Lulong Bo; Jinbao Li; Xiaoming Deng
Journal:  Crit Care       Date:  2012-05-06       Impact factor: 9.097

6.  ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure.

Authors:  Nadia Aspromonte; Michele Massimo Gulizia; Aldo Clerico; Giuseppe Di Tano; Michele Emdin; Mauro Feola; Massimo Iacoviello; Roberto Latini; Andrea Mortara; Roberto Valle; Gianfranco Misuraca; Claudio Passino; Serge Masson; Alberto Aimo; Marcello Ciaccio; Marco Migliardi
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

Review 7.  B-Type Natriuretic Peptide (BNP) Revisited-Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?

Authors:  Toshio Nishikimi; Yasuaki Nakagawa
Journal:  Biology (Basel)       Date:  2022-07-09

8.  Analytical Issues with Natriuretic Peptides - has this been Overly Simplified?

Authors:  Alexander G Semenov; Alexey G Katrukha
Journal:  EJIFCC       Date:  2016-08-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.